A detailed history of Wealth Enhancement Advisory Services, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Wealth Enhancement Advisory Services, LLC holds 17,557 shares of BCRX stock, worth $133,608. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,557
Previous 17,344 1.23%
Holding current value
$133,608
Previous $131,000 0.76%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 10, 2025

BUY
$7.03 - $8.43 $1,497 - $1,795
213 Added 1.23%
17,557 $132,000
Q3 2024

Oct 23, 2024

BUY
$6.41 - $8.69 $34,229 - $46,404
5,340 Added 44.49%
17,344 $131,000
Q2 2024

Jul 16, 2024

BUY
$4.13 - $6.79 $3,068 - $5,044
743 Added 6.6%
12,004 $74,000
Q1 2024

Apr 15, 2024

BUY
$4.89 - $7.65 $55,066 - $86,146
11,261 New
11,261 $57,000
Q3 2023

Nov 13, 2023

BUY
$6.71 - $7.92 $84,237 - $99,427
12,554 New
12,554 $88,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.42B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Wealth Enhancement Advisory Services, LLC Portfolio

Follow Wealth Enhancement Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wealth Enhancement Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wealth Enhancement Advisory Services, LLC with notifications on news.